-
-
-
-
-
-
-
U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTECâ„¢ ODT For The Preventive Treatment Of Migraine
-
-
-
-
-
-
-
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms
-
15,725 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

